AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06007664 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Video to Improve Daily Activity
Description: Participants will be asked to meet individually with an Occupational Therapist (OT) via Zoom to assess activity performance, establish short-term activity goals, and outline an individualized home exercise program. Participants will also be asked to participate in 4 weekly one hour group sessions via Zoom that will include: 1) education; 2) OT facilitated discussion; and 3) activity demonstration, engagement and feedback. The following topics will be covered: mobility, physical activity, pain management, and energy conservation. Participants will be asked to meet individually with the OT via Zoom for 15-20 minutes weekly to answer questions. At the end, participants will be asked to again meet individually with the OT via Zoom to re-assess activity performance and revisit short-term activity goals and the individualized home exercise program. Advisory Committee Members will be asked to make note of intervention activities during their regular interactions with other participants.
Study NCT04895748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFF332
Description: Hif2alpha inhibitor
Study NCT04891770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered intravenously
Study NCT04891770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selgantolimod
Description: Administered as film-coated oral tablets
Study NCT05840809 — intervention group
Intervention type: DRUG
Intervention: First line tuberculosis treatment
Description: This is an observational study - the decision to use first-line tuberculosis treatment will have already been made by the responsible clinician. The study itself does not require any additional intervention.
Study NCT05234437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tigilanol tiglate
Description: Single or multiple Intratumoural treatments of tigilanol tiglate up to a fixed dose level of 3.6mg/m2.~Tigilanol tiglate is a novel, short-chain diterpene ester in early clinical development for local treatment of a wide range of solid tumours.
Study NCT05174611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
Study NCT05655910 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure Surgery Immunonutrition shake
Description: Nutrition shake to support immune health and recovery from surgery.
Study NCT05174611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 112 capsules with 4 bottles, 28 capsules in each bottle.
Study NCT05301179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protein quantity and quality
Description: Participants will ingest Lacto-vegetarian and vegan diets providing different daily protein quantities. The parallel design will test for protein quantity and the cross-over design will compare the effects of the quality of the protein sources in the diet.
Study NCT04895748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: mTOR inhibitor
Study NCT04895748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDR001
Description: anti-PD-1
Study NCT04895748 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIR178
Description: Adenosine A2A antagonist receptor
Study NCT06565026 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: CS-206
Description: Autologous CD34+ hematopoietic stem cell suspension modified by in vitro base editing technique
Study NCT06580301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YK012
Description: The treatments include 2 cycles of induction treatment, 3 cycles of consolidation treatment, and up to 5 cycles of maintenance treatment.
Study NCT06040970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab
Description: Dose 0: Sacituzumab govitecan 7.5 mg/kg~Dose -1: Sacituzumab govitecan 5 mg/kg
Study NCT06040970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 70 mg/m2 IV
Study NCT05457283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Finerenone in different doses, treatment duration will be 540 ±7 days.
Study NCT04953689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conscientiousness Coach
Description: Participants will use the Conscientiousness Coach app to organize their goals and assist them in engaging in more conscientious behaviors. The participant will also be educated about Conscientiousness as it relates to healthy living and accomplishing life goals and values. Participants will receive brief phone calls during weeks 1, 2, 6, and 10 from the research assistant, tracking progress, answering queries, and return visits to the clinic/teleconference will be scheduled for further assistance during week 4 and week 8. These mid-study visits (or 'Booster Sessions') will last approximately 50 minutes and will involve a brief discussion of goal and value progress and app usage; at this in-person meeting/teleconference, similar questions and topics will be covered as in the bi-monthly phone calls. At week 12, there is a treatment termination visit with the principal investigator and research assistant.
Study NCT06290843 — intervention group
Intervention type: PROCEDURE
Intervention: Schroth method
Description: Exercises from Schoth method
Study NCT06293508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Health Communication Intervention
Description: Participants in this group will receive links and materials related to breast cancer screening from official sources (e.g. MOH, Non-governmental organizations (NGOs), etc.) that is already readily available and accessible by the Malaysian public. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
Study NCT06293508 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioural Change Health Communication Intervention
Description: Participants receive health communication materials designed using persuasive behavioural change communication principles and behavior science to promote breast cancer screening. Frequency, duration, and platform of dissemination will be based on findings from Phase 1 of this study.
Study NCT05896150 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoanalgesia AND single-injection paravertebral block
Description: CO2 Cryoanalgesia AND paravertebral block with Bupivacaine 0.5%
Study NCT05896150 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-injection paravertebral block
Description: Paravertebral block with Bupivacaine 0.5%
Study NCT05279976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visualized Education
Description: The child assigned to intervention group 1 will be told the operation preparation room and the pre-anesthesia process through the picture booklet prepared immediately after the pre-test (first measurement). Children included in this group will be provided to touch the bonnet, mask, gloves and self-inflated balloon (representing the ambu device), and the questions of the child and the parent will be answered.
Study NCT05279976 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Children included in intervention group 2 will be given a kaleidoscope. Each child will be given a separate kaleidoscope. It will be ensured that the child is with the parent while the child is looking at the kaleidoscope for an average of 15-20 minutes. After the attempt is over, the kaleidoscope will be presented to the child.
Study NCT05099874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndeavorRx
Description: EndeavorRx is a digital intervention delivered through an action video game that is indicated to improve attention function. EndeavorRx users first complete two discrete tasks: 1) a perceptual discrimination/attention task in which users respond to target stimuli and ignore distractor stimuli (e.g., tapping the screen quickly only when red aliens appear) and 2) a sensorimotor navigation task in which users tilt their device to steer a hovercraft down a river while targeting or avoiding certain objects. Users are subsequently presented with a multitask training session where they complete the perceptual discrimination/attention task and the sensorimotor navigation task simultaneously. Algorithms adapt the program in both real-time and between sessions to automatically adjust the difficulty level.
Study NCT04819971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirelizumab
Description: tislelizumab (intravenously, 200 mg on day 1 of every cycle for 4 preoperative and 12 postoperative cycles)
Study NCT04819971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab(intravenously, 8 mg/kg loading dose, then 6 mg/kg on days 1 of every cycle for 4 preoperative and 12 postoperative cycles)
Study NCT04819971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: docetaxel (intravenously, 50 mg/m2 on day 1 of every cycle for 3 preoperative cycles)
Study NCT04819971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S1 (orally, 400mg/m2 BID on day 1\~14 of every cycle for 3 preoperative and 3 postoperative cycles )
Study NCT04819971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin(intravenously, 100 mg /m2 on day 1 of every cycle for 3 preoperative cycles ;130mg /m2 on day 1 of every cycle for 3 postoperative cycles.
Study NCT06038461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib Combined With Temozolomide and S-1
Description: Phase I:~Surufatinib: 250mg, QD, PO, Q3W; Temozolomide: 200-300mg, d10-d14, QD, PO, Q3W; S-1: 40-60mg, d1-d14, BID, PO, Q3W.~Phase II:~Surufatinib, Temozolomide and S-1：RP2D
Study NCT05283343 — intervention group
Intervention type: DEVICE
Intervention: SP-1P
Description: A subject undergoes corneal thickness measurement with pachymeter.
Study NCT04286581 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-Gel Laryngeal Mask Airway
Description: The I-Gel Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
Study NCT04286581 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu Auragain Laryngeal Mask Airway
Description: The Ambu Auragain Laryngeal Mask Airway is a medical device that keeps a patient's airway open during anaesthesia or unconsciousness.
Study NCT06240702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Group
Description: Unlike the control group, the experimental group will be given a phase II telerehabilitation program and sleep hygiene training for 3 weeks after discharge. Within the scope of the Phase II telerehabilitation program, breathing exercises and calisthenic exercises will be performed at increasing intensity according to the patient's tolerance, 3 days a week for 3 weeks. In addition, walking training will be continued over increasing distances. In addition, it will be aimed to increase sleep quality by giving a sleep hygiene education brochure to the patients in the experimental group. During the sessions, the vital signs and clinical status of the patients will be monitored according to the severity level determined by the finger pulse oximeter device, digital blood pressure monitor, perceived difficulty level (Borg Scale) and maximum heart rate. In addition, patients will be kept in a diary to monitor their compliance with the treatment program.
Study NCT06063148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enrolled Participant
Description: Participant will undergo at most 10 SpO2 measurements paired with at most 10 routine blood gas samples.
Study NCT06484452 — intervention group
Intervention type: DEVICE
Intervention: No Intervention
Description: No Intervention
Study NCT05338775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Talquetamab will be administered as a subcutaneous (SC) injection.
Study NCT05338775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered as a SC injection.
Study NCT05338775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitor
Description: The PD-1 inhibitor will be administered as an intravenous injection.
Study NCT05116722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder Pacemaker
Description: Shoulder pacemaker treatment for 15 - 30 minutes at 3-months, 6-months and 12-months during physical therapy.
Study NCT06435143 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prelivia
Description: Pad applied to skin provide electrical stimulation for 10 seconds every 10 minutes
Study NCT05851313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin-D
Description: The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
Study NCT05851313 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vitamin-D
Description: The intervention group received 600IU of vitamin D supplements every day, one hour after breakfast for 14-16 weeks.
Study NCT05389254 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous glucose monitoring system
Description: use real-time CGM system to check and adjust blood glucose
Study NCT05389254 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: capillary blood glucose monitoring
Description: monitor blood glucose with finger blood; real-time CGM is blind to both participants and researchers
Study NCT05193916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chiglitazar sodium tablets
Description: the drugs will be given orally once a day
Study NCT05193916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: no active drug contained
Study NCT05342051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balneotherapy
Description: immersion in radon, calcium, natrium, bicarbonate content 42 ℃ thermal-mineral water 15 times in 3 weeks, plus usual care. The total mineral substance of the water is 1530 mg/l. The suggested daily time spent in water is 20 minutes altogether with breaks.
Study NCT04875702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: For the TTT-SU group: The dose titration algorithm for allopurinol increases every 4 weeks by 100 mg until the target serum urate of 6 mg/dL is reached or a patient requires 800 mg per day of allopurinol. Subjects will require a blood draw for SU every 4 weeks until reaching the target.~For the TTASx group: Subjects randomized to the TTASx group will receive anti-inflammatory treatments (naproxen, colchicine, and/or prednisone) for up to six flares over the ensuing three months. Urate lowering therapy (ULT) will only be offered after the third flare during the trial.
Study NCT04875702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 250 MG
Description: Naproxen 250 mg p.o. twice daily
Study NCT05256095 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Thinking in Speech
Description: Thinking in Speech is a therapy to help children with autism learn to cope with daily stressors and improve their communication.
Study NCT06585631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CC PrTNER
Description: Participants randomized to CC PrTNER will be assigned a peer coach. They will conduct interviewer-administered behavioral surveys. The surveys provide an in-depth assessment of SU, HIV prevention and care, engagement, and adherence. Behavioral surveys are administered monthly. The coach will discuss with the participant the areas that are flagged by the psychiatrist; provide psychoeducation around areas identified, and work with the participant to identify their health goals and how changes in SU may help feed into self-defined goals. The coach will meet weekly with the consultant addiction psychiatrist who will make a provisional diagnosis and define a treatment plan with clear goals for treatment outcome. Recommendations will be communicated electronically to the HIV or PrEP provider to facilitate implementation. The coach utilizes MI skills to implement the individually tailored to facilitate the adoption and maintenance of health behaviors.
Study NCT06362902 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic right hemicolectomy with transrectal specimen extraction
Description: Laparoscopic right hemicolectomy with transrectal specimen extraction
Study NCT04764864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angioembolization
Description: Via the femoral route, a non-selective pelvic arteriography with a selective embolization of the arterial branches that show direct or indirect signs of injury will be performed.~In the event of persistent hemodynamic instability after selective embolization, non-selective bilateral embolization of the internal iliac arteries will be evaluated.~The material used will vary depending on the characteristics of the injury and the availability of the materials.
Study NCT04764864 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preperitoneal Pelvic Packing
Description: Pfannestiel incision / infraumbilical laparotomy. Dissection of tissues up to and including the transversalis fascia. Inferior to this and anterior to the peritoneum, the preperitoneal cavity is identified.~Inclusion of radiopaque laparotomy gauze in each hemipelvis, from the posterior part (anterior to the sacro-iliac joint) to the most anterior in the retropubic position. Subsequently, the closure is carried out to increase the plugging effect.~A second intervention is required to remove the material in 24-48 hours.
Study NCT05065892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study NCT05065892 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVAX
Description: 2 doses of Covid-19 vaccine
Study NCT04465825 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HITT: intermittent high intensity exercise
Description: Intermittent bouts of 30-60 seconds of exercise at 90% of peak intensity (HITT).
Study NCT06556927 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter yoga
Description: Part 1: Deep Breathing Exercises: Raise the arms up towards the sky and take a deep breath as possible and hold the breath for 4-5 seconds. This application is repeated several times. This section takes approximately 5-10 minutes.~Part 2: Warm-up exercises: Hands are kept parallel to each other and clapped. The tips of the fingers and palms touch each other, the acupuncture points on both hands are stimulated and the individual's energy level increases.~Section 3: Childish Games: In this section there are childish games. These games are visualized in the mind and the participants are asked to raise their arms upwards in the shape of the letter Y.This section takes approximately 10 minutes.~Section 4: Laughter Exercises: Participants are given verbal guidance such as Put your hand on your heart, feel your heartbeat, let's exhale with a smile, let's make a wish or pray and the laughter exercise is terminated. This section takes approximately 15 minutes.
Study NCT06335888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaFol
Description: AzaFol-PET/CT imaging
Study NCT06335888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AzaFol
Description: AzaFol-PET/CT imaging
Study NCT06335888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDG
Description: FDG-PET/CT imaging
Study NCT06335888 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FDG
Description: FDG-PET/CT imaging
Study NCT06585449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-HTT02
Description: ALN-HTT02 will be administered intrathecally
Study NCT06585449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ALN-HTT02
Description: ALN-HTT02 will be administered intrathecally
Study NCT06585449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intrathecally
Study NCT04875702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.6 mg
Description: Colchicine 0.6 mg p.o. once daily
Study NCT04875702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 1.2 mg
Description: Dose escalation to 0.6 mg p.o. twice daily for patients experiencing breakthrough flares or a dose decrease (0.6 mg p.o. every other day) for patients experiencing gastrointestinal intolerance.
Study NCT04875702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen 500 Mg
Description: dose escalation to 500 mg twice daily for patients experiencing breakthrough flares.
Study NCT04875702 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone 40 mg
Description: For flare glucocorticoids: prednisone taper for 8 days, starting with 40mg (oral) daily.
Study NCT06068465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pimavanserin tartrate
Description: pimavanserin tartrate, 34 mg, capsule, once daily by mouth for 6 weeks
Study NCT06068465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo, capsule, once daily by mouth for 6 weeks
Study NCT05892744 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sertraline
Description: 50-200mg/day
Study NCT05834777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icatibant
Description: Icatibant will be administered with an infusion rate of 100µg/kg/h for 15 minutes before their hemodialysis session (pre-infusion) and 50µg/kg/h during their routine hemodialysis session (maintenance infusion).
Study NCT05834777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride will be administered as the same rate as icatibant